New treatment modalities in advanced thyroid cancer

被引：67
作者：
Kapiteijn, E. [1 ]
Schneider, T. C. [1 ]
Morreau, H. [2 ]
Gelderblom, H. [1 ]
Nortier, J. W. R. [1 ]
Smit, J. W. A. [3 ]
机构：
[1] Leiden Univ, Dept Clin Oncol, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Dept Pathol, Med Ctr, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Dept Endocrinol & Metab Dis, Med Ctr, NL-2300 RC Leiden, Netherlands
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷 / 01期
关键词：
molecular pathogenesis; new treatment modalities; thyroid cancer; PHASE-II TRIAL; RECEPTOR RADIONUCLIDE THERAPY; HISTONE DEACETYLASE INHIBITOR; GROWTH-FACTOR-RECEPTOR; REDIFFERENTIATION THERAPY; PROGNOSTIC VALUE; BRAF MUTATION; RADIOIODINE THERAPY; SIGNALING PATHWAY; GENE METHYLATION;
D O I：
10.1093/annonc/mdr117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma. Results of conventional treatment modalities in advanced thyroid cancer have been disappointing and therefore, new therapies are needed. Methods: We searched PubMed, The Cochrane Library, Medline and EMBASE databases and abstracts published in annual proceedings for new treatment modalities in advanced thyroid cancer. We also searched for ongoing trials in www.clinicaltrials.gov Results: Six phase I, 17 phase II and 1 phase III trials with tyrosine kinase inhibitors were carried out. We found 2 pilot studies and 11 phase II trials with redifferentiation therapies, mainly in DTC. For antiproliferative approaches, three phase I and four phase II trials were found. Immunomodulatory gene therapy was tested in a pilot study in ATC patients. Two phase II trials were carried out with immunotherapy. One phase I and nine phase II trials were found with radionucleotide therapy in patients with DTC. Conclusion: The developments in the treatment of advanced thyroid cancer are intriguing. Future trials should aim at combinations of targeted agents with or without other treatment modalities, and will hopefully contribute to further improvement of outcomes.
引用
收藏
页码：10 / 18
页数：9
相关论文
共 106 条
[1]  
AIN KB, 2008, P AN M AM SOC CLIN, V26, P6027
[2]   Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas [J].
Ain, Kenneth B. ;
Lee, Charles ;
Williams, Kevin D. .
THYROID, 2007, 17 (07) :663-670
[3]  
[Anonymous], CANC FACTS FIG 2007
[4]   The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer [J].
Banerji, Udai ;
Camidge, D. Ross ;
Verheul, Henk M. W. ;
Agarwal, Roshan ;
Sarker, Debashis ;
Kaye, Stan B. ;
Desar, Ingrid M. E. ;
Timmer-Bonte, Johanna N. H. ;
Eckhardt, S. Gail ;
Lewis, Karl D. ;
Brown, Kathryn H. ;
Cantarini, Mireille V. ;
Morris, Clive ;
George, Sarah M. A. ;
Smith, Paul D. ;
van Herpen, Carla M. L. .
CLINICAL CANCER RESEARCH, 2010, 16 (05) :1613-1623
[5]  
Bible KC, 2009, J CLIN ONCOL, V27
[6]   Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas [J].
Bodei, L ;
Handkiewicz-Junak, D ;
Grana, C ;
Mazzetta, C ;
Rocca, P ;
Bartolomei, M ;
Sierra, ML ;
Cremonesi, M ;
Chinol, M ;
Mäcke, HR ;
Paganelli, G .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (01) :65-71
[7]  
BRIERE J, 1974, ANN ENDOCRINOL-PARIS, V35, P281
[8]  
Carlomagno F, 2002, CANCER RES, V62, P7284
[9]   Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid [J].
Christian, JA ;
Cook, GJR ;
Harmer, C .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :258-261
[10]   Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma [J].
Coelho, SM ;
Corbo, R ;
Buescu, A ;
Carvalho, DF ;
Vaisman, M .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (04) :334-339
12345678910